
We claim:

- 1). A method of increasing angiogenesis in pathological conditions associated with insufficiencies in vascular perfusion, comprising the steps of:
 - producing an AT₄ receptor agonist; and
 - administering the AT₄ receptor agonist.
- 2). The method of increasing angiogenesis accordingly to claim 1, further comprising the delivery of the AT₄ receptor agonist locally.
- 3). The method of increasing angiogenesis according to claim 1, further comprising the delivery of the AT₄ receptor agonist intravascularly.
- 4). The method of increasing angiogenesis according to claim 1, further comprising the delivery of the AT₄ receptor agonist intramuscularly.
- 5). The method of increasing angiogenesis according to claim 1, further comprising the delivery of the AT₄ receptor agonist intraperitoneally.
- 6). The method of increasing angiogenesis according to claim 1, further comprising the delivery of the AT₄ receptor agonist subcutaneously.
- 7). The method of increasing angiogenesis according to claim 1, further comprising the delivery of the AT₄ receptor agonist orally.
- 8). A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of:
 - producing an AT₄ receptor antagonist; and
 - administering the AT₄ receptor antagonist.

9). The method of inhibiting angiogenesis accordingly to claim 8, further comprising the delivery of the AT₄ receptor antagonist locally.

10). The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist intravascularly.

11). The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist intramuscularly.

12). The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist intraperitoneally.

13). The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist subcutaneously.

14). The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist orally.

15). A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of:

producing an AT₄ receptor antagonist; and
administering the AT₄ receptor antagonist.

16). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising delivery of the AT₄ receptor antagonist locally.

17). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist intravascularly.

- 18). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist intramuscularly.
- 19). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist intraperitoneally.
- 20). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT₄ receptor antagonist subcutaneously.
- 21). The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT₄ receptor antagonist orally.
- 22). A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of:
- producing an AT₄ receptor antagonist; and
 - administering the AT₄ receptor antagonist.
- 23). The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist locally to the tumor.
- 24). The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist intravascularly.
- 25). The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist intramuscularly.
- 26). The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist intraperitoneally.